cyrilzakka/clinical-trials huggingface dataset:
Epidemiology of Infection in Acute Myeloid Leukemia (AML)

In recent years, multiple factors have strongly impacted the epidemiology of infections in patients with acute myeloid leukemia. On the one hand, the availability of new effective antileukemic drugs (i.e. venetoclax, FLT-3 inhibitors, CPX-351) have expanded the pharmacological armamentarium. On the other hand, first, many of them inhere drug-drug interactions with azoles and fluoroquinolones, facing clinicians with the choice of whether to administer antimicrobial prophylaxis or not. Secondly, there is an increase in infections due to multi-resistant agents from both the bacterial and fungal field. Third, the onset of a viral pandemic that had high relevance in these patients in terms of morbidity and mortality.

The aim of this survey is to collect information on the largest possible sample of patients with AML during induction/consolidation/relapsed-refractory treatment, regarding bacterial, viral, fungal infections. We will evaluate the incidence of the various types of infection in relation to the type of treatment that patients will undergo, in order to identify what should be the best antimicrobial prophylactic approach in each subset of patients.


Eligibility Criteria:
Inclusion Criteria:

* Ability to sign the consent form
* Age ≥18 years
* New diagnosis of AML (only cases diagnosed after 01/03/2025), APL are included
* Patients not elegible to any kind of chemotherapy but only best supportive care (BSC)
* AML patients treated with induction treatment, consolidation treatment, or relapsed/refractory (for these latter patients the first diagnosis must not be prior to March 01, 2025)
* All kind of infectious diseases, including parasites.
* Clincally or microbiologically diagnosed infections, including FUO

Exclusion Criteria:

* Hematological diseases, other than AML
* Patients with an AML diagnosis prior to March 2025 but who relapsed during the period under examination
* Patients relapsed after allo or auto-HSCT (Inclusion of post-transplant patients would create an evaluation bias due to the immunological alterations that the transplant procedure causes)
Specific Neurodynamic Exercises on Disability and Neck Pain in Old Women

This is a randomized, parallel, double-blind clinical trial. The main objective is to compare the efficacy of multimodal exercise with specific neurodynamic exercises and multimodal exercise with non-specific exercises in disability and neck pain in women older than 65 years.

The intervention in both groups will be carried out for 4 weeks, with three weekly sessions. Two evaluations will be carried out, a pre-intervention evaluation and a post-intervention evaluation. We will assess neck pain, disability, upper limb strength, cervical mobility, cervical pressure pain thresholds, kinesiophobia and catastrophism.


Eligibility Criteria:
Inclusion Criteria:

* Women older than 65 years.
* Neck pain

Exclusion Criteria:

* Tumors
* Pacemakers
* Fibrillations
* Cardiac pathology or uncontrolled hypertension
* History of severe trauma/recent cervical surgery
* Uncontrolled systemic and inflammatory pathologies
* Congenital collagen compromise
* Presence of difficulties in performing the Initial Evaluation tests
* Language barriers
* Pending litigation or legal claim
Correlation of Right Atrial Strain With Pulmonary Hypertension, Right Ventricular Function And Outcome In Pediatric Patients

This observational study aims to assess correlation of right atrial strain measured by two-dimensional speckle tracking echocardiography with intraoperatively measured pulmonary artery pressures, other indices of right ventricular function and short term postoperative outcome.


Eligibility Criteria:
Inclusion Criteria:

* Undergoing elective cardiac surgery for congenital heart disease with left to right shunt
* Prior evidence of pulmonary arterial hypertension on preoperative echocardiography.

Exclusion Criteria:

* Neonates
* Children with history of previous cardiac surgery,
* Hemodynamic instability
* Non-sinus rhythm
Brow Enhancement Study

Investigation into brow aesthetics using Botox in Conjunction with Juvederm XC as evaluated by patient satisfaction


Eligibility Criteria:
Inclusion Criteria:

* Men and women

Exclusion Criteria:

* Persons who have not had Botox for months.
* Women who are pregnant, breastfeeding, or trying to get pregnant.
Cardiometabolic Health and Inflammatory Resolution

The aim of this study is to determine how inflammatory resolution impacts cardiometabolic health and disease in subjects that are either lean (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2) or obese (\>30.0 kg/m2).


Eligibility Criteria:
Inclusion Criteria:

* Informed signed consent has been obtained from the volunteer.
* The volunteer has a BMI greater than 18.5 kg/m2

Exclusion Criteria:

* The study staff contacting a potential participant perceives that the individual has difficulty understanding the information.
* An MD determines that the individual is on too many medications to participate
* The individual takes a medication that is approved by the MD, but he/she is not willing or not able to wait with any potential morning medication until after their fasted blood-draw.
* The individual is younger than 18 years (relevant for the FAINT-1 and FAINT-2 cohorts)
* The individual states that they have increased bleeding tendency or are using anti-coagulant (blood thinning) medication.
* The individual has some form of chronic inflammation.
* The individual regularly uses medication that affects inflammatory resolution (e.g., low-dose aspirin).
* The individual uses immunosuppressive drugs (eg, methotrexate).
* The individual regularly consumes fish oils (omega 3).
* The individual has significant gastrointestinal problems.
* The individual smokes or uses chewing tobacco.
* The individual has been drinking alcohol two days before the study visit.
* The individual has tattoos or body piercings on the forearms and / or the stomach that can affect the examination.
* The individual does not follow instructions given in the research study.
Optimal Embryonic Stage for Transfer in Poor Responders

A Prospective cohort study including couples with poor responder females who undergoing ICSI

Purpose:

To determine the optimal embryonic stage for transfer in poor responders.

Method:

Patients were divided into day 3 transfer group and day 5 transfer group. All cases had the same stimulation protocol and planning to do fresh embryo transfer. Assessments will be at Day 1, Day 3 and Day 5/6 according to Gardner's criteria 1999. Embryological and clinical data were recorded and then analyzed using SPSS (version 23) statistical software.

Eligibility Criteria:
Inclusion Criteria:

* poor responders females with AMH≤ 1.2ng and have ≤ 5 mature oocytes
* couples whose planning to do fresh transfer
* male partners have normal semen parameters according to WHO 2010.

Exclusion Criteria:

* sperm or oocyte donation
* gestational carriers
FAME: Functional Assessment of a Myoelectric Orthosis Hand Orthoses

The primary study objective is to compare post-stroke upper extremity (UE) movement while wearing a brace called the MyoPro 2 Motion G versus UE movement while wearing a resting splint and no device in stroke survivors with moderate UE dysfunction. During the study, subjects will undergo general training in the operation of the EMG-controlled orthosis and the comparison orthosis, and then guided through a series of standard clinical outcome measures. These outcome measures will allow the researchers to directly compare the relative benefit of the MyoPro 2 Motion G with a resting hand splint and no device in reducing UE impairment and increasing UE dexterity and functional task performance.


Eligibility Criteria:
Inclusion Criteria:

* Manual Muscle Test \>1/5 in the paretic biceps, triceps, finger extensors and finger flexors;
* score \> 10 \< 30 on the Upper extremity Fugl Meyer AND active shoulder flexion of at least 30 degrees with device weight on affected arm;
* Ability to generate consistent, detectable EMG signal from the bicep/tricep upper arm and distal forearm flexor and extensor sensor sites with wrist in neutral, and fingers in neutral. At rest, achieve an EMG of 5 or below on myConfig (wrist and fingers in neutral and elbow extended); with gain at \< 10 and boost \<12, able to reach a threshold of 10 at both bicep and wrist flexors/extensors;
* a single stroke that is the cause of arm impairment, experienced \>12 months ago; if there are additional asymptomatic lesions (as diagnosed by MRI), these subjects may also be included. Those with another symptomatic stroke in addition to the stroke causing arm impairment are excluded;
* score \>70 on the Modified Mini Mental Status Examination;
* age \>18\< 85;
* \> 6 months since previous functional or therapeutic use of an upper extremity myoelectric orthosis;
* Height \>5'0";
* Weight \>110\< 250 lbs.;
* Forearm circumference (at widest part) \<13 in.;
* Bicep circumference \>9 \<15 in.;
* Upper arm length \>5.5 in.;
* Wrist thickness (anterior- posterior) \<1.75 in.;
* ability to stand with minimal assistance

Exclusion Criteria:

* \> 5 on a 0-10 Numeric Pain Rating Scale for pain in the paretic hand, arm or shoulder;
* \> 3 on the Modified Ashworth Spasticity Scale in the paretic elbow, \>2 at wrist or fingers;
* \< 2.5 on the Alexander Apraxia scale; '
* history of neurological disorder other than stroke;
* change in anti-spasticity medications in the last 6 months, and/or receipt of botulinum toxin in the paretic UE in the previous 4 months;
* elbow contracture greater than 10 degrees;
* inability to passively extend fingers while wrist is in neutral;
* other conditions or physical/mental attributes that may undermine safety and/or full participation in the study;
* bilateral hemiparesis.
Patients' Guidance With Onco-Coaching and CANKADO on Systemic Chemotherapy for Metastatic Colorectal Cancer

This is a prospective, single arm, non-interventional project to evaluate the benefit/influence of individualized patient education and guidance with a web-based e-Health platform called CANKADO on patient reported outcomes (PRO) for patients with metastatic colorectal cancer. The focus will be on patient reported outcomes (PRO), distress, Quality of Life (QoL), Global Health Status, complaints and therapy relevant decisions. All patients will be medically treated according to the standards. The experimental arm will include 40 patients. Those patients will receive one initial coaching before start of therapy. Further appointments for coaching will be scheduled depending on individual patient's need. During treatment period the patient is encouraged of joining therapy actively documenting his state of health and occurring health complaints via CANKADO to give the physician a better overview on the process of patient's health behaviour and preparing him for the next doctor-patient consultation.


Eligibility Criteria:
Inclusion Criteria:

* Minumum age of 18 years
* Patient with metastatic colorectal cancer

Exclusion Criteria:

-
Risk Factors and Biomarkers Associated With Recurrence After Excision of Primary Pterygium

This study looks at global gene expression in pterygium and found the derangement of matrix genes in particular to be a feature of pterygium. In the investigators opinion, it would be more beneficial to elicit changes in gene expression before the recurrence of pterygium and by developing a panel of biomarkers that are associated with pterygium recurrence; one would be able to predict the post surgical prognosis of patients after resection.Biomarker levels will be compared to discover a biomarker panel for prediction of recurrence.

A comprehensive questionnaire will be used to evaluate the environmental, biological, physical and behavioral risk factors of associated with the recurrence after pterygium excision.

Slit lamp digital color photographs will be taken on primary and recurrent pterygium and pterygium will be graded in three levels of severity, based on relative transparency of pterygium tissue; grade 1 (transparent), grade 2 (intermediate), and grade 3 (opaque) to see whether the risk factors correlate to the morphology of the pterygium.

Tear samples will be collected before surgery using schirmers strip.Proteins in tear samples will be analyzed using the iTRAQ method.

The transcriptional differences in pterygium and conjunctival tissue samples will be analyzed using western blot, qPCR and immunohistochemistry assays.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of primary and recurrence pterygium
* Must agree to participate in this study
* Must sign informed consent form

Exclusion Criteria:

* Hepatitis
* HIV/AIDS
Efficacy and Safety of SHR8028 Eye Drops for the Treatment of Dry Eye Disease

The study is being conducted to assess the efficacy, safety and tolerability of SHR8028 eye drops in comparison to the vehicle for the treatment of dry eye disease.


Eligibility Criteria:
Inclusion Criteria:

1. Age ≥ 18 years old;
2. Provide written informed consent form;
3. Have a subject reported history of dry eye disease in both eyes for at least 180 days before the screening visit (visit 0);
4. Be currently (within 30 days before visit 0) using over-the-counter (OTC) eye drops, lubricating gels or tear neurostimulator device (such as True TearTM), and/or artificial tears for dry eye symptoms;
5. Have at least one eye meets criteria of moderate to severe dry eye both at visit 0\&1
6. Be able and willing to follow instructions and participate in all study assessments and visits.

Exclusion Criteria:

1. Have any clinically significant slit-lamp findings at visit 0 that require treatment with prescription drugs and/or in the opinion of the investigator may interfere with study parameters, such as trauma, Stevens-Johnson syndrome, or advanced epithelial basement membrane disease;
2. Have dry eye disease secondary to scar formation, such as radiation, alkali burn, cicatricial pemphigus, and destruction of conjunctival goblet cells (i.e., destruction of conjunctival goblet cells caused by vitamin A deficiency);
3. Have active ocular allergy or ocular allergy that may occur during the study;
4. Be diagnosed with an ongoing ocular or systemic infection (bacterial, viral, or fungal), including fever, or be undergoing treatment with antibiotics at visit 0 and visit 1;
5. Be a woman who is pregnant, breastfeeding, or planning pregnancy;
6. Have an uncontrolled systemic disease;
7. Have allergies to investigational medicinal product (IMP) or its components: cyclosporin A or semi-fluorinated alkanes (SFA);
8. Be currently participating in other drug or device trials, or have used other investigational drugs or devices within 60 days before visit 0;
9. Have a condition which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere with the subject's participation in the study significantly;
10. Have received or removed lacrimal duct embolism within 90 days before visit 0, or plan to receive or remove lacrimal duct embolism during the study.
A Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction

This purpose of the study was to evaluate the earliest time to onset of action in adults with erectile dysfunction (often called impotence). In this study vardenafil has been compared to placebo. Patients were asked to fill in questionnaires and a diary in which they filled in details about attempts at sexual activity during study period. Patients received also a stopwatch to record the time of onset of erection. Stopwatch should be started immediately prior to initiating sexual activity and stopped when an erection perceived to be adequate for penetration was obtained.


Eligibility Criteria:
Inclusion Criteria:

* Males with ED for more than 6 months according to the NIH Consensus statement(inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance)
* Heterosexual relationship
* 18 years and older

Exclusion Criteria:

* Primary hypoactive sexual desire
* History of myocardial infarction, stroke or life threatening arrhythmia within the prior 6 months
* Nitrates or nitric oxide donors use
* Other exclusion criteria according to the US Product Information
Different Modalities of Management of Odontogenic Keratocysts

Background The odontogenic keratocysts (OKCs) have been one of the maxillofacial region's most contentious pathological phenomena. Decompression/marsupialization (D/M), enucleation (E), enucleation + chemical cauterization with Carnoy's solution (E+CS), enucleation + peripheral ostectomy (E + PO), as opposed to enucleation + chemical cauterization with Carnoy's solution + peripheral ostectomy (E + CS + PO), were used during surgery to ensure that no epithelial remnants were left behind.

Rationale Through the management of OKC a recurrence could occur, the effectiveness of Decompression/marsupialization (D/M), Enucleation (E), Enucleation+Carnoy's solution chemical cauterization (E+CS), Enucleation+peripheral ostectomy (E+PO), Enucleation+Carnoy's solution chemical cauterization + peripheral ostectomy (E+CS + PO), will be analyzed

Since the middle of the 20th century, the odontogenic keratocyst (OKC) has been one of the maxillofacial region's most contentious pathological phenomena. It was initially misdiagnosed as a primordial cyst. After that, because of its severe clinical behavior and tendency to recur, it was no longer considered to be a part of its classification, also known as a odontogenic tumor. Then, In 2017, the OKC are re-classified as a cystic lesion. But still there is debate about their management. So, this study will be enrolled with the following objectives: to describe how odontogenic keratocysts are managed, to Discover the most favorable approach to manage OKC with the need to stop it from happening again To categorize the odontogenic keratocyst management outcomes into to the subsequent groups: (1) total resolution, (2) partial resolution; (3) Recurrence.

Eligibility Criteria:
Inclusion Criteria:

* All odontogenic keratocysts that are treated by the following surgical treatment modalities:

  1. Enucleation followed by peripheral ostectomy and Carnoy's solution
  2. Decompression/ marsupialization
  3. Enucleation
  4. Enucleation and Carnoy's solution
  5. Enucleation and Peripheral Ostectomy
* Follow-up period 10 years

Exclusion Criteria:

* Cases treated with resection
* Cases showed neoplastic transformation in their pathology
* Cyst Like lesions
Injury Prevention Programs in Overhead Athletes

To evaluate and describe the effect of performing an integrated injury prevention exercises on the variables considered as injury risk factors in overhead athletes

To evaluate and describe the effect of performing fast or 6-8 weeks injury prevention programs on the variables considered as injury risk factors in overhead athletes as glenohumeral rotational range of motion or muscle activation pattern and asymmetries.

Eligibility Criteria:
Inclusion Criteria:

* Signing the informed consent according last version ogf Helsinky Declaration.
* Be involved in a overhead sport for a minimum of 2 years.

Exclusion Criteria:

* Have some pain or disconfort to develop the outcome measurements
Quantification of the Visual Benefits of Soft Toric Contact Lenses Compared to Soft Spherical Contact Lenses

The aim of this work is to undertake a range of vision-related measures with soft toric contact lenses soft spherical contact lenses and spectacle lens correction across a range of levels of astigmatism.

This will be a randomised, crossover, partially subject-masked (for contact lenses only), non-dispensing study, controlled by cross-comparison.

Eligibility Criteria:
Inclusion Criteria:

-

Subjects will only be eligible for the study if:

1. They are of legal age between 18 and 40 years.
2. They understand their rights as a research subject and are willing and able to sign a Statement of Informed Consent.
3. They are willing and able to follow the protocol.
4. They are current wearers of any soft contact lens (i.e. have worn lenses in the last six months).
5. They have refractive ocular astigmatism between 0.00DC and -1.50DC in one or both eyes.
6. They have a spherical component to their ocular refractive error between 0.00 and - 6.00 DS.
7. They could attain at least 0.10 logMAR distance high contrast visual acuity in one eye with the study lenses within the available power range.
8. They can be fitted satisfactorily with both lens types.
9. They own an acceptable pair of spectacles.
10. They agree not to participate in other clinical research for the duration of this study.

Exclusion Criteria:

-

Subjects will not be eligible to take part in the study if:

1. They have an ocular disorder which would normally contra-indicate contact lens wear.
2. They have a systemic disorder which would normally contra-indicate contact lens wear.
3. They are using any topical medication such as eye drops or ointment.
4. They have had corneal refractive surgery.
5. They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.
6. They are pregnant or breastfeeding.
7. They have any ocular abnormality which would, in the opinion of the investigator, normally contraindicate contact lens wear.
8. They have an amblyopic eye, in which case only dominant eye will be assessed for that subject.
9. They have an infectious disease (e.g. hepatitis), any immunosuppressive disease (e.g. HIV) or diabetes.
10. They have a history of severe allergic reaction or anaphylaxis.
11. They have taken part in any other contact lens clinical trial or research, within two weeks prior to starting this study.
The Effect of Osteopatic Cranial Techniques on the Audiometric and Tympanometric Values in Children Suffering From Otitis Media With Effusion.

Children with otitis media with effusion will be treated with osteopatic cranial techniques or with a placebo treatment. Before and after the treatment audiometric and tympanometric measures will take place. This procedure will be repeated 3 times, once a week and every session will last for 30-45 minutes. The fourth week, only audiometry and tympanomtry will be done.


Eligibility Criteria:
Inclusion Criteria:

* children between 3 and 7 years old
* Bilateral otitis media with effusion
* Tympanogram type B

Exclusion Criteria:

* ventilation tubes
* Damage of the tympanic membrane
* Operation of the tympanic membrane
* Other illness e.g. Down, craniofacial abnormalities,...
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®

This study is conducted in Asia. The aim of this post marketing surveillance (PMS) is to assess safety and effectiveness of long-term treatment with Tresiba® (insulin degludec) in patients with diabetes mellitus requiring insulin therapy under normal clinical practice conditions.

A total of 4000 patients will be enrolled to investigate long term (3 years of treatment) safety of Tresiba® and additional 2000 patients will be enrolled to assess the safety in an early stage of the PMS more precisely. At the time of enrolment the patients will be randomly allocated to either 3 years or 6 months observation group.


Eligibility Criteria:
Inclusion Criteria:

* Patients with diabetes mellitus requiring insulin therapy for whom the treating physician has decided to start Tresiba® treatment

Exclusion Criteria:

* Patients who are or have previously been on Tresiba® therapy
* Patients who have previously been participating in this PMS